1 |
R. H. Phillips, M. W. Whitehead, S. Lacey, M. Champion, R. P. H. Thopmson and J. J. Powell, Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subcitrate and colloidal bismuth subcitrate: in vitro data do not predict in vivo efficacy, Helicobacter; 5(3), 176-182 (2000)
DOI
ScienceOn
|
2 |
L. F. Lacey, N. M. Frazer, O. N. Keene and J. T. L. Smith, Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB), Eur. J. Clin. Pharmacol., 47, 177-180 (1994)
|
3 |
식품의약품안정청(KFDA)고시 제2005-31호(2005. 6. 7), 생물학적동등성 시험기준
|
4 |
H. L. Waldum, G. Ovigstad, R. Marvik, E. Brenna, U. Syversen and A. K. Sandvik, The effect of tripotassium dicitrato bismuthate on the rat stomach, Aliment. Phamacol. Ther., 8(4), 425-431 (1994)
|
5 |
F. R. A. Froomes, A. T. Wan, A. C. Keech, J. J. McNeil and A. J. McLean, Absorption and elimination of bismuth from oral doses of tripotassium dicitrato bismuthate, Eur J Clin. Pharmacol.. 37, 533-536 (1989)
DOI
|
6 |
E. J. Prewett, J. Bickley, R. J. Owen and R. E. Ponder, DNA pattems of Helicobacter pylori isolated from gastric antrum, body and duodenum, Gastroenterol., 102(3), 829-833 (1992)
DOI
|
7 |
J. R. Lambert and P. Midolo, The actions of bismuth in the treatment of Helicobacter pylori infection, Aliment. Phamacol. Ther., Suppl 1, 27-33 (Review; 1997)
|
8 |
H. Vanhoe, J. Versieck, L. Vanballenberghe and R. Dams, Bismuth in human serum: reference interval and concentrations after intake of a therapeutic dose of colloidal bismuth subcitrate, Clin. Chim. Acta, 219, 79-91 (1993)
DOI
ScienceOn
|
9 |
A. Slikkerveer, R. B. Helmich, P. M. Edelbroek, G. B. van der Voet and F. A. de Wolff, Analysis of bismuth in serum and blood by electrodermal atomic absorption spectrometry using platinum as matrix modifier, Clin. Chim. Acta, 201(12), 17-25 (1991)
DOI
ScienceOn
|